Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.34 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.34 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296353 | 1.00 | ACACB (0.38) | ACACBGPR119KCNH2MAPTHCRTR1 | |
| SCHEMBL1296417 | 0.88 | ACACB (0.35) | ACACBGPR119KCNH2MAPTPOLB | |
| SCHEMBL1296420 | 0.88 | ACACB (0.35) | ACACBGPR119KCNH2MAPTPOLB | |
| SCHEMBL1294960 | 0.87 | GPR119 (0.39) | ACACBGPR119KCNH2MAPTHCRTR1 | |
| SCHEMBL1294970 | 0.87 | GPR119 (0.39) | ACACBGPR119KCNH2MAPTHCRTR1 | |
| SCHEMBL1295947 | 0.87 | GPR119 (0.48) | ACACBGPR119KCNH2CNR2GUCY1B2 | |
| SCHEMBL1296210 | 0.85 | GPR119 (0.43) | ACACBGPR119KCNH2CNR2 | |
| SCHEMBL1296208 | 0.85 | GPR119 (0.43) | ACACBGPR119KCNH2CNR2 | |
| SCHEMBL1296129 | 0.79 | GPR119 (0.39) | ACACBGPR119CNR2GUCY1B2GUCY1A2 | |
| SCHEMBL1296150 | 0.77 | GPR119 (0.43) | ACACBGPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | ACACB 3305/4885GPR119 1/4885KCNH2 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.